Health Care

Bank of America Securities: Lowered Pfizer (NYSE:PFE) price target to $50 with neutral rating

/ / Health Care / ,

Bank of America Securities released a research report saying that Pfizer’s (NYSE:PFE) guidance for this year’s results indicates that the company expects pandemic-related revenue to decline by more than 60%, resulting in total revenue falling about 30% from the middle of the guidance. The bank said that while it was not surprised by the slowdown in demand, the magnitude of the decline and profit margins affected EPS guidance. Non-COVID-related revenues were also weaker, partially offset by poor performance on the Ibrance and Eliquis franchises. The bank believes investors have been focusing on non-COVID-related businesses given the uncertainty surrounding growth prospects in the post-pandemic period. The report mentioned that Pfizer highlighted several upcoming products that may improve investor sentiment. However, the bank believes they are unlikely to ease growth concerns. The bank continues to be cautious about the group’s long-term growth prospects, with revenue expected to grow at a CAGR of […]

Bank of America Securities: Lowered Pfizer (NYSE:PFE) price target to $50 with neutral rating Read Post »

Moderna (NASDAQ:MRNA):announced updates on its industry-leading mRNA pipeline

/ / Health Care /

January 9, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 48 programs in development, including 36 programs in clinical trials encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities. Respiratory syncytial virus (RSV) vaccine •Pivotal Phase 3 RSV efficacy study (mRNA-1345) in older adults (60+) has enrolled 36,604 participants •Primary endpoints are safety and vaccine efficacy •The Phase 3 RSV study has now accrued the cases required (64 confirmed cases with 2+ symptoms accrued, minimum of 42 required) to complete our first interim efficacy analysis Seasonal influenza vaccine •mRNA-1010 Southern Hemisphere immunogenicity study in adults (18+) is fully enrolled (6,000 participants); data readout expected in 1Q23 •mRNA-1010 Northern Hemisphere efficacy study in older adults (50+) is fully enrolled (22,510 participants); data readout could occur this winter depending upon cases

Moderna (NASDAQ:MRNA):announced updates on its industry-leading mRNA pipeline Read Post »

Moderna (NASDAQ:MRNA):2022 COVID-19 vaccine sales of approximately $18.4 billion

/ / Health Care /

January 9, 2023 / Moderna, Inc. (NASDAQ:MRNA),announced updates on its industry-leading mRNA pipeline. 2022 COVID-19 vaccine sales of approximately $18.4 billion (unaudited). Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals. Potential additional contracts in the United States, Europe, Japan, and other key markets. About Moderna (NASDAQ:MRNA) In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and

Moderna (NASDAQ:MRNA):2022 COVID-19 vaccine sales of approximately $18.4 billion Read Post »

Abbott (NYSE:ABT) raised price target to $122 from $114 by Barclays

/ / Health Care / ,

Barclays Bank analyst Matt Miksic released a research report saying that maintaining a positive interest in Abbott  (NYSE:ABT) with an increased price target of $122 from $114. Miksic noted that while the macro backdrop remains challenging for the medical supplies and equipment industry, and the timing of inflationary pressures, supply chain issues and hospital staffing challenges is not yet clear, Miksic remains optimistic about the industry overall, believing that future product sales trends in the industry will improve, industry staffing is gradually stabilizing, and supply chain and inflation cost issues will also stabilize. Miksic said it will continue to be bullish on Abbott’s stable operating leverage and tailwind prospects for the company’s future. It said the company will have the ability to attract market capital and operate to achieve higher market valuations.

Abbott (NYSE:ABT) raised price target to $122 from $114 by Barclays Read Post »

Abbott (NYSE:ABT)Stock price trend forecast and trading range -2023.1.6

/ / Health Care /

Abbott (NYSE:ABT) Stock price trend forecast and trading range: Updated to: 2023.1.6 (Note: The upper red line in the picture is the resistance, and the lower red line is the support) Analysis from stock chart —————————————————————- Short-term trend: up Sell high and buy low of range : above 20-day moving average Support: 20-day moving average resistance: $112 Stop Loss Price: 20-day moving average price target: $112 Buy the position again: stop fall and rise to 20-day moving average Medium-term trend: rebound High sell low buy range: above 20-day moving average Support: 20-day moving average resistance: $117 Stop Loss price: 20-day moving average price target: $117 Buy the position again: stop fall and rise to 20-day moving average Long-term trend: rebound High sell low buy of range: above 30-day moving average Support : 30-day moving average resistance: $123 Stop Loss price: 20-day moving average price target : $123 Buy the position

Abbott (NYSE:ABT)Stock price trend forecast and trading range -2023.1.6 Read Post »

Evercore ISI Downgrades CVS Health to In-Line, Lowers Price Target to $100

/ / Health Care / ,

Evercore ISI analyst Elizabeth Anderson downgraded CVS Health (CVS) from outperform to be in line with the market, lowering its price target to $100 from $120. Anderson told investors in a research note that a channel check conducted during Medicare Advantage enrollment showed that CVS Health’s 2023 plan offerings were competitive. The analyst said that while the inspection results showed that the company’s Aetna was doing well in some regions, its share growth did not appear to be strong compared to previous years. Anderson believes CVS Health’s valuation in 2023 will bounce back in a relative range pending greater certainty in the final portfolio.

Evercore ISI Downgrades CVS Health to In-Line, Lowers Price Target to $100 Read Post »

Abbott (NYSE:ABT) Stock Price Trend Forecast and Market Analysis-2022.12.30

/ / Health Care /

Abbott (NYSE:ABT) stock price trend forecast and market analysis: 2022.12.30 From the stock chart analysis, the recent stock price rebounded 18% from the previous low point following the main index. The current stock price is more likely to choose the direction of fluctuation, mainly depending on the performance of the index. I think there is a high probability that the stock price will fall to the 60-day EMA again, continuing to test the lower support level downward. Short-term trades above $105, a target price of $112, and a stop loss price of $105. From Analysis from financial statements, Q3 2022 achieved operating income of US$10.41 billion, YoY-4.74%, net profit attributable to common shareholders of US$1.435 billion, YoY-31.67%, and EPS of US$0.81. Quarterly dividend of $0.47 per share. The sales growth rate has turned negative in Q3, the net profit has fallen significantly, and there is a large downside in the

Abbott (NYSE:ABT) Stock Price Trend Forecast and Market Analysis-2022.12.30 Read Post »

Pfizer submitted a marketing application for pentavalent meningococcal vaccine to the US FDA

/ / Health Care /

Pfizer submitted a Biologics License Application (BLA) for MenABCWY, a pentavalent meningococcal vaccine candidate, to the U.S. Food and Drug Administration (FDA) for the prevention of meningococcal disease, the most common serogroup in people aged 10 to 25 years. FDA expects to make a decision in October 2023. Pfizer said its pentavalent meningococcal vaccine MenABCWY, like its own group B meningococcal vaccine Trumenba and GlaxoSmithKline’s meningococcal vaccine Menveo, met the primary and secondary goals of the phase III trial in healthy people aged 10-25 years. Pfizer said Wednesday that if approved, the vaccine would help simplify the meningococcal vaccination schedule and provide the broadest meningococcal seropopulation coverage.

Pfizer submitted a marketing application for pentavalent meningococcal vaccine to the US FDA Read Post »

Japan approves the AstraZeneca blood cancer drug Calquence

/ / Health Care /

Japan’s Ministry of Health, Labour and Welfare approved AstraZeneca’s Calquence for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia (CLL), including small lymphocytic lymphoma (SLL). The approval was supported by data from two trials, including a phase 3 study called ELEVATE-TN.

Japan approves the AstraZeneca blood cancer drug Calquence Read Post »

Scroll to Top